Clinical outcome and safety of rituximab therapy for pemphigoid diseases

Published: 19 Feb 2020 | Version 1 | DOI: 10.17632/7j5vv3rryc.1
Contributor(s):

Description of this data

https://doi.org/10.1016/j.jaad.2019.11.023
Supplemental materials for this retrospective case series including all (n=38) pemphigoid patients at the University of Pennsylvania followed at least 1 year after RTX or until death. Outcomes followed consensus definitions. The primary endpoint was complete remission (CR). Secondary endpoints were CR off therapy (CROT), corticosteroid dose, relapse, serious adverse events (SAEs), and autoantibody titers.

Experiment data files

Latest version

  • Version 1

    2020-02-19

    Published: 2020-02-19

    DOI: 10.17632/7j5vv3rryc.1

    Cite this dataset

    Tovanabutra, Napatra; Payne, Aimee S (2020), “Clinical outcome and safety of rituximab therapy for pemphigoid diseases”, Mendeley Data, v1 http://dx.doi.org/10.17632/7j5vv3rryc.1

Statistics

Views: 4
Downloads: 7

Institutions

University of Pennsylvania

Categories

Autoimmunity, Rituximab, Pemphigoid

Licence

CC BY 4.0 Learn more

The files associated with this dataset are licensed under a Creative Commons Attribution 4.0 International licence.

What does this mean?
You can share, copy and modify this dataset so long as you give appropriate credit, provide a link to the CC BY license, and indicate if changes were made, but you may not do so in a way that suggests the rights holder has endorsed you or your use of the dataset. Note that further permission may be required for any content within the dataset that is identified as belonging to a third party.

Report